Global health experts have always felt that they are fighting a losing battle to galvanise funding to fight diseases of the poor.
Big pharmaceutical companies are understandably reluctant to invest in products for which there is no profitable market. And governments and universities cannot afford to gamble millions on developing a drug that may not even get approved.
This impasse seemed to be coming to an end with the advent of product development partnerships (PDPs), which combine academic know-how with pharmaceutical money.
To read the full, original article click on this link: Biomed Analysis: Public–private health R&D can't stall - SciDev.Net
Author: Priya Shetty
